National Quality Measures Clearinghouse | Cancer - skin rash: percentage of patients treated with agents that block epidermal growth factor receptors (EGFRs) for whom the presence and severity of skin rash was evaluated within one month after starting the treatments and at each visit.

RAND Corporation

Title
Cancer - skin rash: percentage of patients treated with agents that block epidermal growth factor receptors (EGFRs) for whom the presence and severity of skin rash was evaluated within one month after starting the treatments and at each visit.

Source(s)
Dy SM, Lorenz KA, O'Neill SM, Asch SM, Walling AM, Tisnado D, Antonio AL, Malin JL. Cancer Quality-ASSIST supportive oncology quality indicator set: feasibility, reliability, and validity testing. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2010 Apr. 13 p. (Effective Health Care Program research report; no. 24).

full-text:
National Quality Measures Clearinghouse | Cancer - skin rash: percentage of patients treated with agents that block epidermal growth factor receptors (EGFRs) for whom the presence and severity of skin rash was evaluated within one month after starting the treatments and at each visit.